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Abstract Atherosclerosis is characterized by chronic low grade
inflammation of arteries that results in the development of lipid
dense plaques. Chronic inflammation induced by Western-type
diet is associated with the risk of developing atherosclerosis, and
new insights shed light on the importance of metabolic and
functional reprogramming in monocytes and macrophages for
progression of atherosclerosis. This review aims to provide an
overview of our current understanding into how the metabolic
reprogramming of glucose, cholesterol, fatty acid, and amino
acid metabolism in macrophages contributes to inflammation
during atherosclerosis. Recent insights suggest that transcrip-
tional and epigenetic adaptation within innate immune cells
(termed trained immunity) play an important role in the patho-
genesis of atherosclerosis. We propose that metabolic changes
induced by pro-atherogenic lipoproteins partly mediate these
changes in trained macrophages. Finally, we discuss the possi-
bility of manipulating cellular metabolism of immune cells for
targeted therapeutic intervention against atherosclerosis.
Keywords Atherosclerosis . Immunometabolism . Innate
immunememory . Trained immunity . Epigenetic
reprogramming
Introduction
In most patients, acute myocardial infarction and stroke are the
consequence of erosion or rupture of large artery atherosclerotic
plaques and the subsequent local formation of an occluding
thrombus. The risk to develop atherosclerosis is determined to
a large extent by common cardiovascular risk factors such as
smoking, dyslipidemia, hypertension, diabetes, and obesity. In
addition, chronic inflammatory conditions, including rheuma-
toid arthritis and psoriasis, increase atherosclerotic cardiovascu-
lar risk independent from the traditional risk factors.
Atherosclerosis is characterized by a chronic non-resolving
low-grade sterile inflammation of the arterial wall. It predom-
inantly occurs at arterial sites of disturbed laminar flow, where
subendothelial accumulation of apolipoprotein B-containing
lipoproteins is the key initiating step. In the last two decades,
macrophages have been identified as protagonists of athero-
sclerosis and its thrombotic complications [1]. Inflammatory
macrophages are the most abundant immune cells within
plaques, originating from circulating monocytes that bind ac-
tivated endothelial cells and migrate into the intimal layer [2],
as well as from local proliferation of resident macrophages [3].
Lesion formation is markedly reduced when circulating
monocytes are prevented from binding to endothelial cells
[4]. Within the plaque, macrophages orchestrate the progres-
sion of the atherosclerotic process by the uptake of oxidized
low-density lipoprotein particles (oxLDL) and subsequent
foam cell formation. In addition, macrophages respond with
the production of a large variety of pro-atherogenic cytokines
and chemokines upon stimulation with danger-associated mo-
lecular patterns, such as oxLDL and proteoglycans, which are
present in the atherosclerotic milieu [5]. Finally, macrophages
influence plaque stability by regulating collagen production
and by the production of proteases such as matrix metallopro-
teinase [1].
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Within plaques, macrophage phenotype is shaped largely
by external stimuli. The traditional classification into pro-
inflammatory M1 macrophages and anti-inflammatory M2
macrophages was reported to be an oversimplification of re-
ality in which diverse activation signals drive a spectrum of
macrophages [6]. Importantly, these distinct activation states
have different energy requirements. Therefore, it is not sur-
prising that the intracellular metabolism of these macrophages
varies considerably. However, it has only recently emerged
that the intracellular metabolic pathways not only follow the
energy demands of the cells but also actually regulate the
functional state of the cells in response to environmental cues,
such as oxygen and nutrient availability, growth factors, and
cytokines [7, 8]. This plasticity is a characteristic not only of
local plaque macrophages but also of circulating monocytes
and their bone marrow progenitors that are also exposed to
pro-atherogenic stimuli such as lipoproteins, glucose, diet, and
microbiota-derived substances. Complementing this view that
the functional states of macrophages are shaped by tissue mi-
croenvironment is the recent finding that brief encounters of
monocytes with pro-atherogenic stimuli can induce a long-
lasting inflammatory monocyte/macrophage phenotype either
in the bone marrow or in the circulation. This innate immune
memory has recently been termed Btrained innate immunity^
[9, 10].
Trained immunity as a novel mechanism
of atherogenesis
The adaptive immune system, which consists of B and Tcells,
generates specific T cell clones and antibodies that target in-
vading pathogens. This garners highly effective and specific
protection against re-infection by the same pathogen.
Traditionally, innate immune cells were resigned to the task
of nonspecific elimination of the pathogen either by cellular
mechanisms such as phagocytes or NK cells, or humoral
mechanisms such as the complement system. However, a
growing body of evidence demonstrated that monocytes and
macrophages retain memories of past infections rendering
them more or less responsive to re-challenge. This innate im-
mune memory is comprised of a hyper-responsive phenotype
termed trained innate immunity or trained immunity and a
hypo-responsive phenotype termed tolerance. Tolerance is in-
duced experimentally by subjecting monocytes to high doses
of lipopolysaccharides (LPS). Upon maturation into macro-
phages, these tolerized cells are refractory to secondary stim-
ulation. At the other end of the spectrum, trained immunity is
exemplified by increased cell responsiveness after exposure to
β-glucan [11], a component of theCandida albicans cell wall,
or Bacillus Calmette-Guérin (BCG) [12]. Monocytes that
come into contact with a moderate amount of these stimuli
give rise to macrophages that mount an augmented response
towards secondary stimulation. This trained phenotype is also
induced in vivo by BCG vaccination in healthy subjects, with
ex vivo stimulation of circulating peripheral blood mononu-
clear cells showing enhanced responsiveness for up to
3 months [12].
In the context of recurrent infections, trained immunity
provides robust protection against re-infection. This is illus-
trated by the prevention of mortality in mice after lethal C.
albicans challenge when the mice received BCG vaccination
2 weeks earlier [12, 13]. The leading cause of death inWestern
societies is no longer infectious diseases, due to the develop-
ment of antibiotics and vaccinations. In contrast, cardiovascu-
lar disease has replaced infections as the major cause of death.
The role of innate immune memory in propagating chronic
inflammatory states, such as atherosclerosis, is under current
and thorough investigation. In this context, calibration of in-
nate immune cells for heightened inflammatory responses rep-
resents an added risk for the development and progression of
atherosclerosis. Indeed, vaccination with BCG accelerates
atherosclerosis in rabbits fed a cholesterol-rich diet [14].
However, other data suggest that hyperlipidemic mice fed a
high-cholesterol diet had a delayed atherosclerotic plaque for-
mation 6 weeks following BCG injection. It is important to
realize, though, that in these mice, the BCG administration
significantly lowered non-HDL cholesterol levels [15].
Specific to cardiovascular disease, trained immunity can
also be induced by non-microbial pro-atherogenic stimuli,
such as oxLDL and lipoprotein (a). Brief stimulation of iso-
lated human monocytes to oxLDL induces a macrophage phe-
notype that responds with enhanced production of TNFα and
IL-6 to re-stimulation with Toll-like receptor (TLR) 2 and
TLR4 ligands and signaling through the PI3K and MAPK
pathway [16]. Inhibition of histone methylation by the non-
specific methyltransferase inhibitor 5′-methylthioadenosine
completely ablated the training induced by oxLDL suggesting
that epigenetic reprogramming is important for oxLDL-
induced trained immunity. Apart from increases in cytokine
production, oxLDL-trained macrophages exhibited increased
expression of the oxLDL recognition receptors CD36 and SR-
A, as well as reduced expression of the cholesterol efflux
transporters ABCA1 and ABCG1. Functionally, oxLDL-
trained macrophages also exhibited greater oxLDL uptake,
and an increased propensity to form foam cells. Other pro-
atherogenic factors increased in oxLDL-trained macrophages
were the chemokineMCP-1 as well as the collagenasesMMP-
2 and MMP-9, suggesting possible roles for oxLDL-trained
macrophages in the progression of atherosclerosis pathogene-
sis and plaque destabilization. In addition to oxLDL, a pro-
atherogenic-trained macrophage phenotype was obtained by
brief stimulation to lipoprotein (a) [17]. These findings sug-
gest that although trained immunity is beneficial in the context
of recurrent infections, it might actually accelerate the devel-
opment of atherosclerosis.
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In 2014, two landmark papers characterized the epigenetic
and metabolic profile of macrophage innate immune memory
[18, 19]. Epigenetic reprogramming at the level of histone
modifications was identified as crucial intracellular mecha-
nisms that determined the enhanced functional state following
brief exposure of the cells to selected microorganisms and
microbial products. Epigenetic analysis of several activating
histone methylation and acetylation marks revealed distinct
epigenetic signature characteristic of naïve, tolerant, or β-
glucan-trained macrophages [19]. Training with oxLDL cor-
responds with enrichment of H3K4me3 at the promoters of
TNFA, IL6, MCP1, IL8, CD36, SR-A, MMP2, and MMP9
(Fig. 1) [16]. Gene ontology analysis showed that β-glucan
training induces the expression of genes associated with cen-
tral metabolism, most notably with the glycolysis and tricar-
boxylic acid cycle (TCA), spawning the hypothesis that met-
abolic reprogramming is also important for the functional fate
of trained immunity [18].
Recent data suggests that monocytes with a Btrained^ phe-
notype are present in patients with atherosclerosis or associat-
ed risk factors. Monocytes isolated from subjects with elevat-
ed circulating levels of lipoprotein (a) showed a similar in-
creased cytokine production capacity, which was associated
with enhanced endothelial binding and transendothelial mi-
gration, and increased vascular wall inflammation in vivo, as
measured with fluorodeoxyglucose positron emission tomog-
raphy [17]. Circulating monocytes from patients with severe
coronary atherosclerosis elicited a stronger ex vivo pro-
inflammatory cytokine and chemokine response towards stim-
ulation with LPS compared to healthy subjects without ath-
erosclerosis [20]. Curiously, the activating H3K4me3 marks
were reduced at the promoters of TNF, IL-6, and IL-1β in
coronary symptomatic patients compared to controls.
However, the repressive histone modifications H3K9me3
and H3K27me3 were depleted from promoters of genes
encoding TNF and IL-6 of monocytes from symptomatic pa-
tients. Although this epigenetic profile differs from in vitro β-
glucan-trained immunity, it does show that patients with ac-
tive atherosclerosis are epigenetically distinguishable from
healthy controls.
Metabolism of innate immune cells in atherosclerosis
Cellular metabolism of innate immune cells has recently
emerged as an important determinant of immunological re-
sponses. These studies have given rise to the field of
immunometabolism, which has broad implications for human
disease, and is the subject of various recent excellent reviews
[7, 8, 21]. This review will focus primarily on the
Fig. 1 Trained macrophages drive atherosclerosis progression.
Monocytes are recruited into the intima after binding to activated
endothelial cells. Once in the intima, monocytes differentiate into
macrophages. Trained monocytes show higher expression of CCL2,
encoding monocyte chemoattractant protein 1 (MCP-1), which signals
the recruitment of additional monocytes. Furthermore, trained
macrophages produce high levels of pro-inflammatory cytokines such
as TNF alpha, IL6, and IL18. Increased expression of lipid scavenging
receptors CD36 and SR-A enhances the gross uptake of modified lipids,
generating foam cells which aggregate together in the lipid core. Plaque
destabilization results from increased matrix metalloproteinase (MMP)
production from pro-inflammatory macrophages, promoting degradation
of the fibrous cap. These changes in gene expression are at least partly
driven by the enrichment of H3 histones methylated at lysine 4 at regu-
latory promoters
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immunometabolism of monocytes and macrophages and how
the inner energy processing of these cells contributes to the
entropy of atherosclerosis.
It is currently appreciated that cellular metabolism is not
merely a source of energy for the cell. Through the breakdown
of nutrients, ATP is produced which is used for the various
energetically demanding processes within the cell, but the
intermediate metabolites of the various intracellular metabolic
pathways also serve many important biological roles in their
own rights. A classic example is the divergent use of arginine
by so-called classically (LPS/IFNγ) activated macrophages
(formally known as M1 macrophages), and alternatively (IL-
4/IL-13) activated macrophages (M2 macrophages) [22]. The
pro-inflammatory M1 macrophages synthesize nitric oxide
(NO) from L-arginine via inducible-nitric oxide synthase
(iNOS). M1 macrophages produce NO to signal important
cues including vasodilation, insulin secretion, and angiogene-
sis, as well as being an important microbicidal agent. The
immune regulatory M2 macrophages on the other hand catab-
olize arginine via arginase (Arg1), producing L-ornithine in
the process. L-ornithine can then be further broken down into
polyamines and L-proline which can be used to support cell
growth and division, as well as serving as an essential building
block for collagen production contributing to wound healing
and tissue repair.
Another stark difference between the metabolic activi-
ties of macrophages is the difference in their glucose us-
age. LPS/IFNγ-activated macrophages metabolize glucose
primarily via glycolysis, while IL-4/IL-13-induced macro-
phages metabolize glucose via oxidative phosphorylation
(OXPHOS). Glycolysis and OXPHOS diverge after pyru-
vate production, where in glycolysis, pyruvate is converted
into lactate via lactate dehydrogenase (LDH), in total pro-
ducing two molecules of ATP for each molecule of glu-
cose, while in OXPHOS, pyruvate is shuttled into the
mitochondria and enters the tri-carboxylic acid (TCA) cy-
cle netting 32 molecules of ATP for every molecule of
glucose. The reliance on glycolysis by energetically active
cells seems counterintuitive at first; however, this metabol-
ic effect is well known for its importance in driving the
growth of cancer cells, termed the Warburg metabolic
shift. Although less efficient, glycolysis can result in a
rapid increase in ATP production, and, moreover, produces
various important metabolites that fuel the pentose phos-
phate pathway (PPP) as well as fatty acid synthesis (FAS)
for the production of amino acids and fatty acids vital for
carrying out various cellular activities, as well as
supporting cell growth and division. Cells with an arche-
typal Warburg effect also maintain a TCA cycle, but have
two blockades after citrate and succinate resulting in the
accumulation of these metabolites [23, 24]. Citrate is vital
for phospholipid and cholesterol synthesis, both crucial for
formation of new membranes, a central process during cell
activation. In turn, succinate activates HIF-1α and induces
IL-1β production [25].
In this review, we discuss in detail the potential role of
immunometabolism in the pathophysiology of atherosclero-
sis. We propose changes in intracellular metabolism in circu-
lating monocytes and bone marrow progenitors that are driven
by exposure to systemic pro-atherogenic stimuli, such as lipo-
proteins, glucose, catecholamines, and products that are de-
rived from the diet and gut microbiome. Once differentiated
into plaque macrophages, the functional state can be further
influenced by stimuli in the micro-environment of the athero-
sclerotic plaque, such as modified lipoproteins, and hypoxia
[26]. Finally, we propose that the susceptibility for these trig-
gers to modulate intracellular metabolism and functional state
is influenced by the genetic background of these cells (Fig. 2).
Glycolysis as a determinant of inflammation
in atherosclerosis
Monocytes stimulated with inflammation-inducing stimuli,
such as LPS or oxLDL, switch towards preferential glycolytic
metabolism. The pro-inflammatory NF-κB regulates the ex-
pression of HIF-1α, leading to the increased expression of the
GLUT-1 glucose transporter, which consequently enhances
the uptake of glucose to meet increasing demand. Another
important activator of the HIF-1α transcription factor is hyp-
oxia. Atherosclerotic plaques are rich with regions of hypoxia
where oxygen availability is limited.When a cell is exposed to
low oxygen levels, the HIF-1α transcription factor is stabi-
lized and initiates glycolytic metabolism, reducing the cell
reliance on OXPHOS, as well as increasing the expression
of the key glycolysis proteins GLUT1, hexokinase II (HK-
II) , and 6-phosphofructo-2-kinase/fructose-2, 6-
bisphosphatase (PFKFB3), resulting in increased glycolytic
flux [27]. These activated macrophages take up large quanti-
ties of glucose and begin to secrete high levels of cytokines.
Indeed, mouse models of atherosclerosis have demonstrated
the co-localization of hypoxia, HIF-1α expression, and FDG
uptake in macrophages within the atherosclerotic plaque
[27–29]. With regard to using FDG uptake as measure for
glycolysis, a recent study concluded that this uptake might
not reveal all differences in glycolytic rate; it appeared that
stimulation of peritoneal macrophages with M-CSF or GM-
CSF resulted in a 4.7- and 2.8-fold increase in glycolytic ac-
tivity, whereas FDG uptake was increased to a similar extent
in both situations [30].
An elegant proof-of-principle experiment showed that
Ldlr−/− mice were less susceptible to atherosclerotic plaque
formation when HIF-1α was knocked out in myeloid cells
[28]. GLUT-1 expression was negatively affected in these
HIF-1α-deficient cells, suggesting a role for glucose metabo-
lism in this protective knockout.
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HIF-1α is also important for initiating macrophage infiltra-
tion into tissue. Underlying this increased ability to migrate was
the induction of pyruvate dehydrogenase kinase isozyme 1
(PDK1) by HIF-1α [31]. PDK-1 catalyzes the conversion of
pyruvate into lactate. Inhibition of glycolysis using 2-deoxy-D-
glucose suppressed migration, suggesting a non-dispensable
role for glucose metabolism in initiating tissue migration by
macrophages in response to hypoxia.
It was recently shown that monocytes from patients with
symptomatic atherosclerosis expressed higher levels of
glycolysis-related genes, including HK2, PFKFB3, and
PKM1 [20]. Shirai and colleagues showed that circulating
monocytes from patients with coronary artery disease had an
increased appetite for glucose, and that upon ex vivo differen-
tiation into macrophages, maintained their appetites. Pyruvate
kinase M2 (PKM2) was highly upregulated in these macro-
phages, which phosphorylates the transcription factor STAT3
resulting in higher levels of IL-6 and IL-1β production, con-
tributing to the inflammatory state of these cells [24]. PKM2
was also shown to stabilize the production of ROS by the
mitochondria contributing the oxidative potential of these
macrophages.
The origin of these circulating cells with increased glycol-
ysis in patients with atherosclerosis remains unclear; however,
there is evidence that metabolic changes with increased gly-
colysis are already present in hematopoietic stem and progen-
itor cells (HSPCs). Glucose uptake was increased in athero-
matous plaques, spleens, and the bone marrow of the ApoE−/−
mouse model of atherosclerosis [32]. The oxygen consump-
tion and proliferation were increased in HSPCs. In addition,
mitochondrial oxygen consumption rate was also higher in
these cells and circulating leukocytes, distinguishing this met-
abolic state from the classical Warburg metabolism [32].
There were parallel increases in citrate, fumarate, and malate
concentrations in circulating leukocytes. However, succinate
was not increased, likely due to an increased succinate dehy-
drogenase expression. Studies have shown that conversion of
succinate and pyruvate into the TCA cycle is essential for
HPSC expansion. Mice with defective cholesterol efflux
transporters ABCA1 and ABCG1 in the myeloid lineage are
characterized by a massive expansion and proliferation of
HSPCs [33]. Further studies revealed that intracellular choles-
terol loading activates GLUT1 expression, glycolysis, and ox-
idative phosphorylation via IL-3Rβ/GM-CSF signaling [34].
Although glycolysis is clearly important for fueling the
inflammation that drives the progression of atherosclerosis,
it appears that an increased glycolytic rate in macrophages
alone is not enough to induce atherosclerosis. Induced
Fig. 2 Divergent metabolic pathways in monocytes and plaque resident
macrophages. Monocytes and their bone marrow progenitors are exposed
to various stimuli, including lipoproteins, glucose, and diet/microbiota-
derived substances that can modify the monocyte phenotype by changing
the intracellular metabolism, as mentioned in the text. Once within ath-
erosclerotic plaques, macrophage metabolism can be modified further by
stimuli that are present in the atherosclerotic plaque micro-environment,
including hypoxia, modified lipoproteins, and cytokines
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GLUT1 overexpression in myeloid cells could not induce ath-
erosclerotic lesions in Ldlr−/− mice, despite having increased
glycolytic flux, activated PPP, and a compensatory reduction
in fatty acid β-oxidation. Importantly, overall oxygen con-
sumption was not increased in these cells [35]. Similarly, over-
expression of GLUT1 in the mouse J774 macrophage cell line
showed increases in glycolysis and flux through the PPP;
however, no significant increase was seen in inflammatory
gene expression.
Recently, it was demonstrated that a large portion of mac-
rophages inside the atherosclerotic plaque originate frommac-
rophage proliferation within the plaque rather than via mono-
cyte recruitment into the plaque and macrophage differentia-
tion [3]. Importantly, glycolysis fuels the PPP to synthesize
amino acids needed for the increased protein, RNA, and DNA
synthesis burden of inflamed macrophages. Increased amino
acid production by the PPP is also important for the produc-
tion of nucleotides used for the escalated transcription in acti-
vated macrophages. This boost in nucleotide synthesis may be
important for accommodating DNA replication needed for
this enhanced cellular proliferation of activated macrophages.
Furthermore, recent evidence shows the importance of
non-coding RNAs in potentiating atherosclerosis through
metabolic reprogramming. Mir-33, which is triggered by a
Western diet, specifically has been shown to be important in
regulating a pro-inflammatory phenotype by inhibiting
AMKP, which suppresses fatty acid oxidation (FAO) and en-
hances glycolysis [36, 37].
Another mechanism that potentially links activation of gly-
colysis and PPP with atherogenesis is the production of
NADPH, owing to activation of the PPP. NADPH oxidases
(NOX), of the mitochondria and phagosomes, remove elec-
trons from NADPH and transfer them to oxygen molecules
generating oxygen radicals that play an important role in the
phagocytic degradation of invading pathogens. Oxygen radi-
cals are also important for contributing to the oxidative stress
within the atherosclerotic plaque by oxidizing proteins and
fatty acids, most famously LDL molecules. An interesting
observation is that only pro-inflammatory macrophages like
LPS/IFNγ-activated and trainedmacrophages have an activat-
ed PPP [18], suggesting that PPP is vital for facilitating the
increased cellular dynamics of activated macrophages, as well
as integrating this inflammatory process in the pathogenesis of
atherosclerosis [25].
In a series of recent studies, it has been shown that trained
immunity is also critically dependent on activation of the gly-
colytic rate. Importantly, training with both β-glucan and
BCG activates glycolytic flux in monocytes, but a classical
Warburg metabolic shift is observed only in β-glucan-trained
cells; stimulation with BCG results in upregulation of both
glycolysis and oxidative phosphorylation [38, 39]. Arts et al.
demonstrated that genetic variation in key glycolytic enzymes
such as HK2 and PFKP determined the magnitude of BCG-
induced training, illustrating the concept that genetic variation
affects the susceptibility of the innate immune system for
training [38]. The causal role for glycolysis in trained immu-
nity has been validated by the observation that trained immu-
nity is completely prevented by pharmacological blockers of
glycolysis [18]. For oxLDL-induced training, the role for gly-
colysis remains to be determined.
Intracellular cholesterol metabolism
and atherosclerosis
The lipid bilayer that constitutes the membranes of cells and
organelles is rich in cholesterols. This cholesterol is important
for maintaining the structural integrity and fluidity of the
membrane as well as signal transduction. As such, cholesterol
plays many important roles in facilitating the formation of
immunological synapses and endocytosis of foreign bodies,
as well as cellular growth and proliferation among many other
cellular processes. Apart from their structural importance, iso-
prenoid intermediates of the cholesterol synthesis pathway are
used for the prenylation of signaling molecules, which accom-
modate their integration into the cell membrane, allowing for
the transduction of important immunological processes.
It is well known that a major risk factor for the develop-
ment of atherosclerosis is the presence of high levels of mod-
ified cholesterol, most notably oxLDL. Within atherosclerotic
plaques, oxLDL is taken up by macrophages resulting in
cholesterol-laden macrophages often dubbed foam cells.
Foam cells contribute to the pathogenesis of the plaque by
secreting high amounts of pro-inflammatory cytokines and
chemokines, as well as by the production of matrix metallo-
proteinases (MMP) which degrade the extracellular matrix of
the plaque [40, 41].
Modified LDLs are highly pro-inflammatory, and as
discussed previously, can induce a trained immune phenotype
when stimulated for 24 h. Key metabolic pathways upregulat-
ed in macrophages trained with β-glucan or BCG include the
cholesterol synthesis pathway, and inhibition of cholesterol
synthesis with statins abrogate β-glucan-induced trained im-
munity both in vivo and in vitro [39]. The role of the choles-
terol synthesis pathway for oxLDL-induced training remains
to be established.
It is obvious that the control of cholesterol influx versus
efflux is vitally important for the progression of atherosclero-
sis. At the base of this regulation are key transcription factors.
Liver X receptor (LXR) increases the expression of cholester-
ol efflux transporters, controlling the amount of cholesterol
removed from the cell. LXR activation has potent anti-
inflammatory effects, at least partly due to the inhibition of
TLR-2, TLR-4, and TLR-9 signaling to their downstream
NF-κB and MAPK effectors via changes in membrane lipid
composition through ABCA1, which disrupts the recruitment
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of MyD88 and TRAF6 [42]. In contrast, a previous study
reported that LXR activators ameliorate atherosclerosis in
Ldlr−/− mice independent from ABCA1 and ABCG1 in mye-
loid cells [43].
SREBP1c, a member of the protein SREBP family, turns
on the fatty acid synthesis pathway, a pathway upregulated in
pro-inflammatory LPS/INFγ-activated macrophages [44].
SREBPs are located within the ER, where they are retained
by cholesterols, desmosterol, and oxysterols. SREBPs are re-
leased when intracellular concentrations of these metabolites
drop critically. The released SREBPs migrate into the nucleus
and drive the expression of LDL receptors as well as genes
involved in the cholesterol biosynthesis pathway and the fatty
acid synthesis pathway. In addition, SREBP1a is a target gene
of NF-κB and are therefore induced by inflammation [45].
Rather surprisingly, it was recently reported that foam cells
derived from murine peritoneal macrophages have an anti-
inflammatory phenotype, due to accumulation of desmosterol
[46], which contrasts with the finding that in an atherosclerotic
plaque environment, foam cells have an increased inflamma-
tory gene expression [47]. Due to a suppressed DHCR24,
desmosterol is no longer converted into cholesterol, and accu-
mulates within foam cells. Desmosterol is an important acti-
vator of LXR, resulting in the suppression of SREBP1 and 2
processing, as well as the inhibition of inflammatory gene
expression. However, foam cells are also characterized by
enhanced expression of pro-inflammatory cytokines.
Therefore, it is likely that cues from the atherosclerotic envi-
ronment, which were not present in this experimental set up,
drive the pro-inflammatory phenotype of foam cells.
The importance of cholesterol homeostasis for immune
function in the context of atherosclerosis is illustrated by var-
ious observations in murine models of atherosclerosis: several
animal studies have reported that LXR agonists can reduce
atherosclerotic plaque formation [40]. Moreover, hypercho-
lesterolemia and impaired cholesterol efflux in myeloid cells
promote atherosclerotic lesion formation by increased prolif-
eration of HSPCs [40].
Fatty acid oxidation and fatty acid synthesis
In a broader sense, intracellular fatty acid synthesis and oxidation
play an important role in regulating the inflammatory output of
the macrophage. Namely FAO is the primary source of energy
production used by anti-inflammatory IL-4/IL-13-activated mac-
rophages [21, 48]. LPS/IFNγ-activated macrophages on the oth-
er hand downregulate FAO, favoring glycolytic metabolism for
their energy demands. Transport of long-chain fatty acids into the
mitochondria via CPT1 induces fatty acid oxidation in macro-
phages. Fatty acid oxidation is supported by the gene regulatory
effects of STAT6 and PPAR-γ-co-activator 1β (PGC1β), in re-
sponse to IL-4, which work together to suppress inflammatory
signaling [49, 50]. FAO metabolism in macrophages has been
tied to these cells’ anti-inflammatory responsiveness. Induced
overexpression of CPT1, predictably resulted in increased rates
of FAO, and coincided with decreased production of inflamma-
tory cytokines [51].
By contrast, fatty acid synthesis is generally associated
with a pro-inflammatory macrophage phenotype [52, 53].
As discussed earlier, SRBEP1c expression lays at the base
of this enhanced fatty acid synthesis pathway in LPS/IFNγ-
activated macrophages; a key gene upregulated in this path-
way is the multi-complex enzyme FASN. The increased fatty
acid synthesis resulting from FASN expression plays an im-
portant role in the generation of pro-inflammatory LPS/IFNγ-
activated macrophages [44]. The relevance of this pathway for
atherosclerosis development is highlighted by the observation
that macrophage-targeted deletion of Fasn reduces atheroscle-
rotic plaque formation and foam cell formation in ApoE−/−
mice, probably through inactivation of LXRα [54].
Within the atherosclerotic plaque lay many regions of hyp-
oxia. Hypoxia, as well as NF-κB, are important activators of
HIF-1α, which stimulates stearoyl-coenzyme A desaturase,
an important enzyme in FAS. It has been shown that hypoxia
enhances FAS while suppressing FAO, thereby promoting
triglyceride-laden macrophages [55]. Specifically, stearoyl-
coenzyme A desaturase (SCD) is activated under hypoxic
conditions driving the synthesis of monounsaturated fatty
acids from palmitic acid. Increased intracellular levels of un-
saturated fatty acids (oleic acid, linoleic acid, and arachidonic
acid), but not saturated fatty acids, stimulate a pro-
inflammatory phenotype by upregulating IL-1α production
in foam cells [56]. However, SCD deficiency in the bone
marrow of Ldlr−/− mice sees no changes in macrophage in-
flammatory function or lesion size, despite having defective
cholesterol efflux [57].
Under certain conditions, machinery from FAO may par-
ticipate in inflammatory processes, thereby repurposing the
mitochondria away from solely producing ATP. A few studies
have shown that oxidized palmitate generated byCPT1A fuels
mitochondrial respiration resulting in ROS production, which
subsequently activates the NLRP3 inflammasome [58–60]. It
was recently shown that CPT1A expression was elevated in
early atherosclerotic lesions in mice [61], potentially placing
this novel approach to metabolic repurposing in the develop-
ment of atherosclerosis. Although this remains hypothetical,
studies like these highlight the interconnectedness of various
metabolic pathways in inflammatory signaling.
Amino acid metabolism and atherosclerosis
Although often left in the shadows of glycolysis and fatty acid
metabolism, the metabolism of amino acids can have some
profound and important roles in inflammation contributing to
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vascular pathology. In the context of atherosclerosis, the me-
tabolism of arginine, and its byproduct NO, is vitally impor-
tant for the early stages of the disease [62]. Risk factors for
coronary heart disease are associated with decreased bioavail-
ability of NO and endothelial dysfunction [63]. NOS metab-
olism of arginine, through an oxidation of the guanidine-
nitrogen terminal of L-arginine, produces NO and citrulline
as a result. NO plays an important role in maintaining the
homeostasis of vascular tissue by preventing the abnormal
proliferation of vascular smooth muscle cells, maintaining
leukocyte interaction with the vascular wall, and regulating
the presentation of antigens, as well as in maintaining vascular
tone and growth [64].
Inflammation within the atherosclerotic tissues gives rise to
many ROS species. NO interacts with ROS, giving rise to the
even more reactive nitrogen species (RNS) such as peroxynitrite
[65, 66]. Apart from lowering the bioavailability of NO, conver-
sion into RNS have other unfavorable effects on proteins in the
extracellular milieu by causing protein nitration, an important
sign of tissue damage. Importantly, peroxynitrite also oxidizes
lipoproteins within the intima, further generating the pro-
atherosclerotic oxLDL. Classically activated macrophages are
well characterized as elevating their expression of the
(inducible) iNOS; elegant in situ hybridization experiments have
demonstrated elevated iNOS expression by macrophages within
atherosclerotic lesions when compared to healthy arterial tissue
[67, 68]. Foam cells within atherosclerotic tissue were shown to
have elevated levels of both COX-2 and iNOS. It is likely that
cross-talk between these two metabolic pathways produce high
levels of peroxynitrite furthering inflammation within the athero-
sclerotic plaque [69].
NADPH oxidases are an important source for ROS produc-
tion. Nox1 affects atherosclerosis formation, as Nox1 genetic
deletion in ApoE−/− mice reduces atherosclerosis [70]. Bone
marrow transplantation experiments revealed that NADPH
oxidase activity in myeloid cells is indeed essential for LDL
oxidation in the vascular wall [71]. As previously mentioned,
trained macrophages are characterized by activation of the
PPP, which is important for NADPH generation.
Interestingly, ROS production was upregulated in monocytes
trained with BCG and oxLDL, whereas β-glucan-induced
training did not induce this effect [72].
One of the more well-studied amino acids for its role in
stabilizing inflammation is glutamine. Glutamine is important
for the induction of IL-1 by macrophages in response to LPS
stimulation [73]. Glutamine also has potential roles in macro-
phages microbicidal capacity by aiding in the generation of
NO by feeding into the arginine synthesis pathway. Due to
these potentially important roles in the immune functioning of
macrophages, glutamine is hypothesized to play an important
role in sepsis and burns.
Rom et al. conducted experiments to determine the
atherogenicity of various amino acids in a murine
macrophage-like cell line [74]. They found that glutamine
had pro-atherosclerotic effects on these macrophages: macro-
phages supplemented with glutamine had an increased triglyc-
eride mass as a result of enhanced triglyceride biosynthesis by
increased SREBP1 and DGAT1 expression. In addition, glu-
tamine supplementation to ApoE−/− mice was associated with
an enhanced ROS generation in peritoneal macrophages. [74].
Glutamine feeds into the TCA cycle by direct conversion
into glutamate, α-ketogluterate, and succinate semialdehyde,
serving as an important determinant of IL-4 macrophage po-
larization [23]. This provides the substrates fumarate and suc-
cinate which replenish the broken TCA cycle. It was recently
shown that macrophages trained with β-glucan have an en-
hanced glutaminolysis, and that this process is vital for the
induction of a trained macrophage phenotype in response to
β-glucan [39]. In trained macrophages, a marked increase in
fumarate and succinate accumulation was noted. Intriguingly,
stimulation of monocytes with an excess of fumarate for the
first 24 h of the differentiation protocol also resulted in en-
hanced TNF and IL-6 production, and correlated with
H3K4me3 epigenetic marks at the promoters of their respec-
tive genes. It was demonstrated that fumarate directly inhibits
the histone demethylase KDM5 which correlated with in-
creased training. Providing the macrophages with α-
ketogluterate, the substrate for KDM5 activity, increase
KDM5 availability and suppressed the fumarate trained phe-
notype. These experiments demonstrate the complex interplay
between epigenetic, metabolic, and inflammatory pathways
leading to innate immune memory. The role of glutaminolysis
for oxLDL-induced training remains to be determined.
Epigenetic memory and metabolic memory are
interconnected
A crucial question is how themetabolic changes described in this
review ultimately connect with gene expression and inflamma-
tory phenotype of the cells. There is accumulating evidence that
epigenetic reprogramming is at the center of this mechanism.
The Diabetes Control and Complications Trial (DCCT) and
the follow-up Epidemiology of Diabetes Interventions and
Complications (EDIC) study compared intensive glucose control
to conventional glucose control in patients with type I diabetes
mellitus [75, 76]. The goal of the DCCT trial was to determine
the effect of strict glucose lowering on the development and
progression of vascular complications of type I diabetes. The
EDIC trial then subjected all patients to the intensive treatment
plan and monitored their progression. Most striking was the ob-
servation that patients subjected to conventional treatment during
DCCT developed more severe complication during the EDIC
phase, when compared to patients that received intensive treat-
ment during DCCT, despite identical treatment regimens in the
follow-up period. This suggests long-term memory from the
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periodwhen patients had elevated glucose levels, which has been
termed hyperglycemic memory [77] or legacy effect [78]. A
follow-up was conducted on a few volunteers of the EDIC trial
where epigenome-wide analysis of H3 acetylation showed an
increase of this mark in monocytes of patients that were treated
with the convention treatment [79]. These data strongly suggest
that long-term epigenetic memory may be influenced by glucose
metabolism. In addition, various intermediate metabolites func-
tion as substrates or cofactors of epigenetic enzymes, which has
been the subject of excellent previous reviews [77, 80].
Various metabolites serve as important substrates or cofac-
tors for epigenetic enzymes. Histone acetyltransferase uses
acetyl-CoA as the essential acetyl donor during the acetylation
of histone lysine residues [81]. Acetylated histone marks, such
as H3K9ac and H3K27ac, are associated with active pro-
moters and enhancers [82, 83]. Histone deacetylases
(HDACs) on the other hand decrease chromatin accessibility
and inhibit gene transcription by removing acetyl groups from
lysines. In this process, the metabolic cofactor NAD+ is es-
sential for deacetylation of histones by the sirtuin family of
HDACs [84]. Histone methylation is written by histone meth-
yltransferases, which rely on S-adenosyl methionine [85].
Methylated histones serve many diverse and counter-
regulatory functions within the cell. Most notably,
H3K4me1, H3K4me3, and H3K36me3 are generally enriched
at active promoters and enhancers [86]. By contrast,
H3K9me3 and H3K27me3 are known as repressive marks
due to their enrichment on silent genes. Lysine-specific his-
tone demethylase 1A (KDM1A) erases histone methylation
by relying on FAD oxidative potential [87, 88]. The histone
demethylase Jumonji is dependent on the TCA intermediate
α-ketoglutarate [89], adding to the pool of necessary cofactors
that drive histone modification flux within the nucleus.
In the context of trained immunity, genome-wide
reprogramming of H3K4me1, H3K4me3, and H3K27Ac in
β-glucan-trained cells has been described [19]. Moreover,
training with BCG and β-glucan as well as with oxLDL was
completely prevented by co-treatment with the nonspecific
histone methyltransferase inhibitor methylthioadenosine [12,
16, 18]. As mentioned before, for β-glucan-induced training,
it was elucidated that fumarate accumulates from glutamine
replenishment of the Krebs cycle, and in turn inhibits the
KDM5 family of H3K4 demethylases, which subsequently
leads to maintenance of this important epigenetic mark of
open chromatin in trained monocytes [39].
Clinical relevance and future directions
Despite optimal treatment of traditional cardiovascular risk
factors with cholesterol-lowering agents and antihyperten-
sives, a significant residual cardiovascular risk remains.
Therefore, the inflammatory component of atherogenesis has
recently gained interest as potential treatment target.
Currently, several large clinical trials are exploring whether
treatment with anti-inflammatory agents such as methotrexate
and the anti-IL-1β-antibody canakinumab is able to prevent
cardiovascular events in high-risk populations [90]. The fur-
ther elucidation of the metabolic reprogramming in the devel-
opment of atherosclerosis might aid in the development of
more targeted treatment strategies to prevent or treat
atherosclerosis.
Interestingly, some drugs that are already in use in clinical
practice for decades, such as metformin and statins, are now
described to interfere with key metabolic pathways that drive
innate immune activation in the context of atherosclerosis.
More specific compounds that inhibit the glycolytic rate might
have the potential to limit atherosclerosis. Interestingly, partial
and transient inhibition of glycolysis, even inmice in vivo, has
proven to be able to limit pathological angiogenesis, a process
in which activation of endothelial cell glycolysis is a major
driving force [91]. Tumor endothelial cells are also character-
ized by a hyper-glycolytic metabolism, and blockade of the
glycolytic enzyme PFKFB3 was able to reduce cancer cell
invasion and metastasis [92]. These examples suggest that
similar strategies might prove to be beneficial in the context
of atherosclerosis.
As a separate layer of metabolic regulation, non-coding
RNAs offer an exciting possible pharmacological target in
the treatment of atherosclerosis. In Ldlr−/− mice on a
Western diet, miR-33 promotes a pro-inflammatory macro-
phage phenotype by fueling glycolysis and repressing FAO
via inhibition of AMKP [37]. This in turn represses the ex-
pression of ALDH type 2 which regulates retinoid acid syn-
thesis, which can promote the development of anti-
atherosclerotic FOXP3+ Tregs. Indeed, systemic treatment
with miR-33 inhibitors for 8 weeks prevented this metabolic
switch and profoundly reduced atherosclerosis progression.
In summary, evidence is accumulating that innate immune
cell metabolism is affected by systemic pro-atherogenic fac-
tors in the circulation and bone marrow niche, and by the local
atherosclerotic plaque environment, and that this shifts these
cells into a pro-atherogenic phenotype that contributes to pro-
gression of atherosclerotic lesions. Further elucidation of the
underlying mechanisms might provide novel markers of car-
diovascular risk and novel pharmacological targets in the bat-
tle against cardiovascular diseases. This maladaptive immune
function contrasts the beneficial effects of long-term activa-
tion of the innate immune system in the context of vaccination
or infectious diseases. Understanding this distinction as well
as the immunometabolic differences between acute inflamma-
tion and chronic metabolic disease are important avenues of
investigation moving forward.
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